Insights Into Acute Myeloid Leukemia (AML) Northeast

Perspectives on management of newly diagnosed and relapsed/refractory AML

Northe – August 17, 2020
Purchase Report

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Example Agenda

Download the meeting agenda

View Agenda

REPORT SNAPSHOT

Insights on the following AML therapies were obtained

  • azacitidine
  • clofarabine
  • cytarabine and daunorubicin (ie, 7+3)
  • decitabine
  • enasidenib
  • gemtuzumab ozogamicin
  • gilteritinib
  • glasdegib
  • liposomal daunorubicin and cytarabine
  • midostaurin
  • sorafenib
  • venetoclax

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated virtual roundtable discussion focusing on treatment of AML was held on August 17, 2020.
  • Disease state and data presentations were developed in conjunction with a medical expert from the University of Colorado
  • The group of advisors comprised 8 community oncologists from the Northeast (USA)
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.